Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets Other stock markets 02:14:20 23/01/2026 am IST			5-day change	1st Jan Change
0.007000 ^USD	+366.67%		+6,900.00%	+366.67%

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73T 74.3T 69.55T 63.46T 1L 81.77L 1L 8L 3L 40.93L 3L 3L 1.37Cr	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	39.16L 33.94L 31.77L 28.99L 54.56L 37Cr 55.47L 3.73Cr 1.46Cr 19Cr 1.47Cr 1.44Cr 62Cr	EV / Sales 2021	93,97,88,53,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/23/31	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/23/30	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/22/11	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
13/22/13	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/22/31	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
12/22/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/22/17	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/22/16	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/22/28	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/22/18	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/21/11	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

07/23/07	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/23/31	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/23/21	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/22/13	Rapid Therapeutic Science Laboratories Updates Patents	AQ
11/22/11	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Share Price

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news : Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

1 day	+366.67%
1 week	+6,900.00%
Current month	+6,900.00%
1 month	+6,900.00%
3 months	+16.67%
6 months	+16.67%
Current year	+366.67%

Current year	0		0.01
1 year	0		0.01
3 years	0		0.05
5 years	0		12.5
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/12/21	Texas Mdi, Inc.	Don	Company	20,00,000	1.0332%
27/12/21	Sean Berrier	Don	Executive/Senior Manager	20,00,000	1.0332%
27/08/21	Henry Punzi	Other	Director	1,25,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.09	-
Net income	-28.68L -24.85L -23.27L -21.23L -39.95L -27Cr -40.62L -2.73Cr -1.07Cr -14Cr -1.08Cr -1.05Cr -46Cr	-17.95L -15.55L -14.56L -13.29L -25L -17Cr -25.42L -1.71Cr -66.89L -8.57Cr -67.39L -65.92L -29Cr
Net Debt	17.93L 15.54L 14.55L 13.27L 24.98L 17Cr 25.4L 1.71Cr 66.83L 8.56Cr 67.32L 65.85L 29Cr	38.31L 33.2L 31.08L 28.36L 53.36L 37Cr 54.26L 3.64Cr 1.43Cr 18Cr 1.44Cr 1.41Cr 61Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+366.67%	+6,900.00%	+118.75%	-80.00%	1.9T
YUNNAN BAIYAO GROUP CO.,LTD	-0.70%	-1.68%	-9.25%	-6.56%	1.34TCr
DONG-E-E-JIAO CO., LTD.	-0.81%	-1.79%	+4.58%	+3.87%	507.18Cr
BEIJING TONGRENTANG CO., LTD	-0.99%	-3.41%	-32.01%	-56.10%	505.93Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-0.12%	+0.48%	+4.20%	-30.78%	417.73Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.13%	-2.70%	-13.13%	-5.79%	365.66Cr
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-0.93%	-2.77%	-3.64%	+2.27%	350.38Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.64%	-2.02%	-4.55%	+16.50%	343.87Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.44%	0.00%	-13.66%	-16.09%	246.95Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+0.71%	-1.18%	-2.89%	+42.72%	188.22Cr
Average	+36.16%	-0.29%	+4.84%	-12.99%	427.01Cr
Weighted average by Cap.	-0.66%	-0.34%	-8.46%	-9.29%